Project Name: Cardiff and Vale Post Coronary Revascularisation Lipid Optimisation Service

Project Summary:

This is a Collaborative Working Project (“CWP”) between Cardiff and Vale University Health Board, Novartis, Amgen, Amarin and Daiichi Sankyo.

This CWP aims to establish and integrate a comprehensive post-acute coronary syndrome lipid optimisation service for patients who have undergone a revascularisation procedure (acute or planned) within CAVUHB to improve patient outcomes and reduce the risk of future cardiovascular events and to reduce health care disparity and inequalities by ensuring the service is available to all patients who present to CAVUHB with Acute Coronary Syndrome (“ACS”) & undergo revascularisation without discrimination.  

The CWP design encompasses the implementation of designated 3–6-month follow-up appointment system, the establishment of a dedicated post Myocardial infarction (“MI”) / lipid service that provides patient education and support, and promotion of health-related behaviours.  

The service will provide a rehabilitation service for post-ACS patients, primarily those who have experienced an acute MI and are undergoing revascularisation procedures. Due to the diverse nature of post-ACS conditions, the clinic will be available to all patients post-revascularisation, whether acute or planned, ensuring that everyone who could benefit from a review is given the opportunity for assessment.

Expected Benefits:

Anticipated Patient Benefits:

  • Reduced risk of further cardiovascular events by adhering to lower lipid lowering target of 50% reduction in LDL-C and a value less than 1.4mmol/L.
  • Initiation and monitoring of appropriate lipid-lowering therapies      
  • Designated 3 month follow up which is currently only occurring in 20% of patients.  
  • Designated point of contact post coronary revascularisation
  • Access to nurse prescriber reducing the wait for treatment      
  • Health education and support
  • Equitable access to genetic lipid testing for identification of FH, FCS, elevated Lp(a) and others. With an increase in number of patients at higher CV risk being identified and subsequently managed for other CV risk factors as well as cascade testing for family members, as appropriate
  • Reduction in health inequalities 

Anticipated CW Partner Benefits:

  • Adherence to NICE, ESC and Heart UK guidelines for lowering lipids post-ACS
  • Identification of patients at risk of FH
  • Increased awareness/identification of patients with elevated Lp(a) levels. 
  • Identification of other genetic lipid conditions
  • Cost benefit associated with reduction in admissions because of reduced ACS in patients who have already had ACS.  
  • Dedicated post-coronary revascularisation lipid optimisation service with a clear role within the cardiology service.
  • Relieve burden on existing services trying to carry out post-coronary revascularisation lipid testing.
  • Increased use of lipid-lowering therapies in line with their licenses.

Anticipated Novartis Benefits:

  • Better understanding of overall customers’ and patients’ needs.
  • Optimal use of medicines, aligned to national and / or local guidelines (including Novartis medicines) in appropriate patients.
  • Increased insight into post ACS patient pathway.
  • Insight into effective genetic risk factor screening, and subsequent management of high-risk patients. 

Expected Start Date & Duration: July 2025 for 30 months

FA-11458668-1 | June 2025